Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab

PURPOSE: Despite selection based on human epidermal growth factor receptor 2 (HER2) overexpression, not all HER2-positive patients benefit from trastuzumab therapy. Recent reports indicate that trastuzumab treatment failure may be associated with immune system dysfunction. We examined the prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales: Che, Yi-Qun, Zhang, Yue, Wang, Di, Liu, Hui-Ying, Shen, Di, Luo, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825475/
https://www.ncbi.nlm.nih.gov/pubmed/31754298
http://dx.doi.org/10.2147/DDDT.S212610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825475/
https://www.ncbi.nlm.nih.gov/pubmed/31754298
http://dx.doi.org/10.2147/DDDT.S212610

Ejemplares similares